Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics

The Time for Cytokine Therapeutics Is Now

We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.

The Power of the Platform

To address the key limitations of current cytokine therapeutics and cell therapies, we are developing potentially paradigm-changing medicines using three distinct protein engineering platforms. These include our cytokine partial agonist, orthogonal cytokine + cell therapy and surrogate cytokine technologies.

The Pipeline to Advance Our Mission

Using our team’s cumulative expertise and our proprietary cytokine platforms, we are developing a broad, deep pipeline of selective immunotherapies against a wide range of important targets for the treatment of cancers and inflammatory diseases.